Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court’s Copaxone Ruling Could Increase Expert Witness Testimony

This article was originally published in The Pink Sheet Daily

Executive Summary

High court rules Federal Circuit should have granted deference to district court’s decision on meaning of Copaxone patent claim; Federal Circuit must now reconsider its finding that the patent is invalid.

You may also be interested in...



Generic Relabeling Speed Could Get Supreme Court Review

Supreme Court asks the Solicitor General to weigh in on whether a state tort claim that Teva did not immediately update its generic Fosamax labeling is preempted by federal law; thousands of such suits have arisen in wake of high court’s Mensing decision.

Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan

Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel